Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 101Xls
2D Structure
Also known as: 41859-67-0, Bezalip, Cedur, Bezafibrat, Difaterol, Befizal
Molecular Formula
C19H20ClNO4
Molecular Weight
361.8  g/mol
InChI Key
IIBYAHWJQTYFKB-UHFFFAOYSA-N
FDA UNII
Y9449Q51XH

An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
2.1.2 InChI
InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
2.1.3 InChI Key
IIBYAHWJQTYFKB-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
2.2 Other Identifiers
2.2.1 UNII
Y9449Q51XH
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azufibrat

2. Bfizal

3. Befibrat

4. Beza Lande

5. Beza Puren

6. Beza-lande

7. Beza-puren

8. Bezabeta

9. Bezacur

10. Bezafibrat Pb

11. Bezafisal

12. Bezalip

13. Bezamerck

14. Bm 15.075

15. Bm-15.075

16. Bm15.075

17. Cedur

18. Difaterol

19. Durabezur

20. Eulitop

21. Lipox

22. Reducterol

23. Regadrin B

24. Sklerofibrat

25. Solibay

2.3.2 Depositor-Supplied Synonyms

1. 41859-67-0

2. Bezalip

3. Cedur

4. Bezafibrat

5. Difaterol

6. Befizal

7. Azufibrat

8. Sklerofibrat

9. Bezafibrato

10. Bezafibratum

11. Bezatol

12. Bezafibratum [inn-latin]

13. Bezafibrato [inn-spanish]

14. Bezatol Sr

15. Bm-15.075

16. Bezatol Sr (tn)

17. 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic Acid

18. Bm 15.075

19. 2-(p-(2-(p-chlorobenzamido)ethyl)phenoxy)-2-methylpropionic Acid

20. Bm-15075

21. Nsc-758174

22. 2-[4-[2-(4-chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic Acid

23. Bm15075

24. Propanoic Acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-

25. Mls000028533

26. Chembl264374

27. Durabezur

28. Reducterol

29. Bezabeta

30. Bezacur

31. Bezamerck

32. Eulitop

33. Solibay

34. Chebi:47612

35. Lipox

36. Bezafibrat Pb

37. Y9449q51xh

38. Beza-lande

39. Beza-puren

40. Regadrin B

41. 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic Acid

42. Propanoic Acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-

43. Ncgc00016850-01

44. Smr000058298

45. Bezafibrate 100 Microg/ml In Acetonitrile

46. Bezafibrato [spanish]

47. 2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic Acid

48. Bezalip Retard

49. Cas-41859-67-0

50. Dsstox_cid_9869

51. Dsstox_rid_78826

52. Dsstox_gsid_29869

53. 2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic Acid

54. Lo 44

55. 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic Acid

56. 2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic Acid

57. 2-[p-[2-p-chlorobenzamido)ethyl]phenoxy]-2-methylpropionic Acid

58. Bf-759

59. Ccris 9085

60. Bm 15075

61. Sr-01000000106

62. Einecs 255-567-9

63. Brn 4267656

64. Unii-y9449q51xh

65. Bezalip Sr

66. Bezafibrate,(s)

67. Bezafibrate [usan:inn:ban:jan]

68. Pem

69. Prestwick_724

70. Mfcd00078970

71. Benafibrate

72. Spectrum_001443

73. Opera_id_376

74. Bezafibrate [mi]

75. Prestwick0_000378

76. Prestwick1_000378

77. Prestwick2_000378

78. Prestwick3_000378

79. Spectrum2_000922

80. Spectrum3_001500

81. Spectrum4_000325

82. Spectrum5_001079

83. Spectrum5_001967

84. Bezafibrate [inn]

85. Bezafibrate [jan]

86. Bezafibrate [usan]

87. Bezafibrate [mart.]

88. Schembl16299

89. Bezafibrate [who-dd]

90. Bezafibrate-d6(dimethyl-d6)

91. Bspbio_000535

92. Bspbio_001314

93. Bspbio_003119

94. Kbiogr_000034

95. Kbiogr_000669

96. Kbioss_000034

97. Kbioss_001923

98. Mls001148205

99. Bezafibrate, >=98%, Solid

100. Divk1c_000092

101. Spectrum1502046

102. Spbio_000824

103. Spbio_002456

104. Bpbio1_000589

105. Gtpl2668

106. Dtxsid3029869

107. Bdbm28701

108. Bezafibrate (jp17/usan/inn)

109. Hms500e14

110. Kbio1_000092

111. Kbio2_000034

112. Kbio2_001923

113. Kbio2_002602

114. Kbio2_004491

115. Kbio2_005170

116. Kbio2_007059

117. Kbio3_000067

118. Kbio3_000068

119. Kbio3_002619

120. 2-[4-[2-(4-chlorobenzamido)ethyl]phenoxy]isobutyric Acid

121. Ninds_000092

122. Bezafibrate [ep Monograph]

123. Bio2_000034

124. Bio2_000514

125. Hms1361b16

126. Hms1569k17

127. Hms1791b16

128. Hms1921h16

129. Hms1989b16

130. Hms2089f04

131. Hms2092b12

132. Hms2096k17

133. Hms2233e22

134. Hms3261d21

135. Hms3369b13

136. Hms3402b16

137. Hms3650k22

138. Hms3652m22

139. Hms3713k17

140. Pharmakon1600-01502046

141. Bcp03700

142. Hy-b0637

143. Zinc3956919

144. Tox21_110645

145. Tox21_301845

146. Tox21_500500

147. Ccg-39683

148. Nsc758174

149. S4159

150. Akos005107743

151. Propionic Acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-

152. Tox21_110645_1

153. Ab03023

154. Ac-6817

155. Bcp9000398

156. Db01393

157. Hs-0040

158. Lp00500

159. Nsc 758174

160. Sb17361

161. Sdccgsbi-0051715.p003

162. Idi1_000092

163. Idi1_033784

164. Ncgc00016850-02

165. Ncgc00016850-03

166. Ncgc00016850-04

167. Ncgc00016850-05

168. Ncgc00016850-06

169. Ncgc00016850-07

170. Ncgc00016850-08

171. Ncgc00016850-09

172. Ncgc00016850-10

173. Ncgc00016850-11

174. Ncgc00016850-12

175. Ncgc00016850-15

176. Ncgc00016850-25

177. Ncgc00023317-03

178. Ncgc00023317-04

179. Ncgc00023317-05

180. Ncgc00023317-06

181. Ncgc00023317-07

182. Ncgc00023317-08

183. Ncgc00255376-01

184. Ncgc00261185-01

185. Bb166159

186. Bezafibrate, Analytical Reference Material

187. Bcp0726000153

188. Sbi-0051715.p002

189. 2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy)

190. Ab00052265

191. B3346

192. Ft-0622617

193. Sw196871-4

194. D01366

195. D70191

196. Ab00052265-15

197. Ab00052265_16

198. Ab00052265_17

199. 859b670

200. Q577387

201. Sr-01000000106-3

202. Sr-01000000106-4

203. Sr-01000000106-5

204. W-106291

205. Brd-k46018455-001-06-0

206. Brd-k46018455-001-17-7

207. Sr-01000000106-10

208. Bezafibrate, European Pharmacopoeia (ep) Reference Standard

209. 2-(4-(2-parachlorobenzamidoethyl)phenoxy)-2-methylpropionic Acid

210. 2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic Acid

211. 2-[4-(2-{[(4-chlorophenyl)carbonyl]amino}ethyl)phenoxy]-2-methylpropanoic Acid

212. Bf; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl Propanoic Acid

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 361.8 g/mol
Molecular Formula C19H20ClNO4
XLogP33.8
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count7
Exact Mass361.1080858 g/mol
Monoisotopic Mass361.1080858 g/mol
Topological Polar Surface Area75.6 Ų
Heavy Atom Count25
Formal Charge0
Complexity452
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Bezafibrate is an antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. The activity of triglyceride lipases (lipoprotein lipase and hepatic lipoproteinlipase) involved in the catabolism of triglyceride-rich lipoproteins is increased by bezafibrate. In the course of the intensified degradation of triglyceride-rich lipoproteins (chylomicrons, VLDL) precursors for the formation of HDL are formed which explains an increase in HDL. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL-receptor-mediated lipoprotein catabolism. Elevated fibrinogen appears to be an important risk-factor, alongside the lipids, smoking and hypertension, in the development of atheroma. Fibrinogen plays an important role in viscosity, and therefore blood flow, and also appears to play an important role in thrombus development and lysability. Bezafibrate exerts an effect on thrombogenic factors. A significant decrease in elevated plasma fibrinogen levels can be achieved. This may lead, amongst other things, to a reduction in both blood and plasma viscosity. Inhibition of platelet aggregation has also been observed. A reduction in blood glucose concentration due to an increase in glucose tolerance has been reported in diabetic patients. In the same patients, the concentration of fasting and postprandial free fatty acids was reduced by bezafibrate.


5.2 MeSH Pharmacological Classification

Hypolipidemic Agents

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)


5.3 ATC Code

C10AB02

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


C10AB02

S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448


C10AB02

S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448


C - Cardiovascular system

C10 - Lipid modifying agents

C10A - Lipid modifying agents, plain

C10AB - Fibrates

C10AB02 - Bezafibrate


5.4 Absorption, Distribution and Excretion

Absorption

Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%.


5.5 Metabolism/Metabolites

Hepatic.


5.6 Biological Half-Life

1-2 hours


5.7 Mechanism of Action

It is generally accepted that bezafibrate is likely an agonist of PPAR-alpha. However, certain other investigations have also suggested that the substance might also elicit some effects on PPAR-gamma and PPAR-delta too.